This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,995 to Cambium Oncology LLC to develop a novel immunotherapeutic drug called ANT308-FC3 fusion for the treatment of acute myeloid leukemia (AML). The funding will support preclinical studies to determine the potency of the drug candidate in activating human T cells, its anti-leukemia activity in mouse models, and its stability and pharmacokinetics (Phases 1 and 2). The goal is to generate an Investigational New Drug (IND) package to support a Phase 1 clinical trial of the ANT308-FC3 fusion in AML patients. This project aims to advance a first-in-class immunotherapy to enhance treatment outcomes for AML, a prevalent and deadly hematological malignancy with a 5-year survival rate of only 32%.
Generated 2/25/25, 3:46 AM